Optimi Health Corp. (OPTH) — Optimi Health said it will supply GMP 40 mg and 60 mg MDMA capsules for MAPS Israel's 'Healing October 7th' clinical program, an open-label, multicenter PTSD study approved by the Israeli Ministry of Health.
The 168-participant trial, sponsored by Sheba Medical Center, compares individual versus group MDMA-assisted therapy, and Optimi confirmed it had already completed its first export shipment to Israel — extending its international commercial supply footprint beyond Australia.
Source: biospace.com
For the rest of that week's sector news, read our week in review.